poh ramping it up

At the risk of labouring a point – if you haven’t already, take time to step back and consider where POH was with respect to their pharma and derma divisions just last September/October. Remember? There were just three projects known to be active–the TPM/oxycodone patch, which was in limbo awaiting patch redesign with Labtec, the TPM/diclofenac gel collaboration with Themis Medicare in India and an ongoing Japanese assessment of TPM to consider whether it was suitable for use in a prescription diclofenac product. That was the sum total.

Fast forward to June 2013. Diclofenac gel is now commercialised and ready for roll out through both Themis and Novartis. Nippon Zoki’s assessment of TPM was positive and has progressed to the current development of a TPM/ diclofenac prescription product for the US market. POH’s TPM/ oxycodone patch has not only been redesigned, it’s been further improved, has returned to the clinic and we are now waiting for trial results. Development of a TPM/injectable antibiotic formulation was announced in October, a TPM/ oxymorphone patch in December and a TPM topical oxycodone patch in February. By March, positive results had already been announced for Phase I clinical trials of the TPM/oxymorphone patch. In May, retinoic acid and ketoconazole were added to the 2013 clinical program schedule and we learned that a third opioid was to join oxycodone and oxymorphone in development. Now in June, it appears that two more non-opioid pain products are being planned.

And while all of this has been occurring in the pharma and derma divisions, POH has been collaborating with the US Department of Agriculture on a bovine mastitis treatment, working with ENA to develop five separate revolutionary racing horse supplements, establishing BioElixia in the United States and manufacturing TPM toning cream for US nutritional giant, GNC.

I am frankly gobsmacked by the speed and aggressivity of Phosphagenics’ expansion. It speaks volumes about company commitment and confidence, it hints at fantastic results coming out of the clinic and it positively screams to me of anticipated income well over and above the recently announced tax rebates.

Who needs to ramp when the company itself is ramping it up in this fashion?